Abbott will acquire Exact Sciences for $21 billion, adding Cologuard and expanding its diagnostics portfolio as analysts highlight growth and valuation momentum.
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Exact Sciences’ third quarter results received a positive response from the market, reflecting strong revenue growth and robust execution in its core screening business. Management attributed the performance to increased adoption of Cologuard, expansion of care gap programs with payers, and a record number of new ordering providers. CEO Kevin Conroy highlighted the company's ability to screen an additional 250,000 people compared to last year, citing “accelerating health systems integrations and a record number of ordering providers.” The introduction of Cologuard Plus and deepening relationships with health systems were also key contributors.
Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, offering a convenient excuse to take profits after strong year-to-date rallies.
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 20% year on year to $850.7 million. The company’s full-year revenue guidance of $3.23 billion at the midpoint came in 2.2% above analysts’ estimates. Its non-GAAP profit of $0.24 per share was 49.4% above analysts’ consensus estimates.
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 20% year on year to $850.7 million. The company’s full-year revenue guidance of $3.23 billion at the midpoint came in 2.2% above analysts’ estimates. Its non-GAAP profit of $0.24 per share was 49.4% above analysts’ consensus estimates.
